341 pharmaceutical companies published in income rankings (with list)

According to data released by the National Bureau of Statistics, enterprises above the scale of the pharmaceutical manufacturing industry in 2020 achieved operating income of about 110.939 billion yuan, down 2.3% year-on-year.
but it is encouraging that the decline in cumulative growth is narrowing, indicating that the pharmaceutical market has picked up significantly since the start of the second quarter.
: Data from the National Bureau of Statistics, China Business Industry Research Institute, for reference.
according to the China Business Industry Research Institute, the number of loss-making enterprises in the first half of 2020 was 1,696, with a loss of 22.9%, and the total loss amounted to 12.57 billion yuan, an increase of 53.3% year-on-year.
From china's market chemical raw materials industry and chinese medicine industry output, in the first half of 2020, China's chemical raw materials production of 1.293 million tons, a cumulative decrease of 8%, the production of Chinese medicine 1.039 million tons, a cumulative decrease of 12.2%.
, the overall situation is more serious.
From the semi-annual results of 341 listed companies that have published semi-annual reports, and China's pharmaceutical industry, its revenue is also the first negative growth, but due to the medical devices, consumables health care sector, driven by a doubling of net profit growth, profits maintained a growth trend, if excluding such sub-sectors, the overall operation of the pharmaceutical industry consistent with negative growth.
half-year revenue decline, profit slightly increased in the first half of this year, the net profit of listed pharmaceutical companies, compared with last year, there was a reversal, overall from the first half of last year the overall situation of "increase income does not increase profits" to "increase profits do not increase income", which is also in the first half of this year's capital market has been fully reflected, especially the epidemic prevention materials and vaccines market mostly out of the doubling or even several times the market.
Specifically, through the statistics of 341 pharmaceutical companies revenue and net profit indicators found that the total operating income of listed pharmaceutical companies decreased by 1.72% YoY, while the growth rate of net profit in the same period increased by more than 10%, mainly due to the doubling of net profit in the health care industry, mainly in the category of epidemic prevention materials.
Comparing the changes in revenue and net profit, the growth rate of net profit in all sectors except The Chinese medicine industry is significantly higher than the growth rate of operating income, which can be seen as a result of the increase in the overall price level of pharmaceuticals caused by the factors of the epidemic.
: data from Tonghuashun, sub-sector classification according to the letter, data for reference.
the results of each performance disclosure, there have always been a few happy a few sad.
Because there are no special effects drugs in this new crown outbreak, pharmaceutical companies have basically no direct beneficiaries, while epidemic prevention materials such as masks, temperature measuring instruments and related diagnostic reagents are direct beneficiaries.
, Zhende Medical, Anglo Medical, Da'an Gene and other enterprises have achieved several times the growth.
but more enterprises due to the resumption of work and production restrictions, marketing and marketing activities are limited, consumer access to purchase and other factors greatly affected the enterprise's operating income and profits.
44 of the 341 companies reported net profit, a loss of 12.9 percent, nearly 10 percentage points lower than the statistics bureau's figures.
in terms of the magnitude of the change, nearly half of enterprises compared with the same period last year, a decline of 160, more than the number of statistical enterprises 46%, it can be seen that its proportion is high, more enterprise performance by the impact of the new crown epidemic.
the direct beneficiaries of the outbreak achieved greater growth Through performance data found that in the first half of 2020 net profit growth of more than 5 times, in addition to brother technology due to the year-on-year net profit of basic 0, low base to achieve substantial growth, the rest of the realization of substantial growth is Health care enterprises, mainly to provide related to epidemic prevention materials enterprises, net profit growth rate of more than 5 times the basic situation of enterprises and the main business areas are as follows: Note: data from Tonghuashun, sub-sector classification according to Tongdaxin, the main business distribution according to the annual report of the enterprise, data for reference.
strong, arms enterprises, research and development enterprises and vaccine enterprises to make a lot of net profit is an important indicator to reflect the ability of enterprises to make money and expand the scale of production and operation.
the first half of this year, but from the major pharmaceutical companies' net profit situation, there are still nine enterprises to maintain the same period last year more than 1 billion net profit.
Among them, the most outstanding performance is to benefit from the new crown outbreak of the device enterprises Meirui Medical, known in the industry as the innovative drug "water seller" CRO company drug Mingkangde and vaccine enterprises Zhifei Bio three enterprises last year on the basis of net profit of more than 1 billion, another increase of more than 30%.
addition, Hengrui Pharmaceuticals is one of the few pharmaceutical companies with a half-year net profit of more than $1 billion and a double percentage increase in revenue and net profit in the event of this year's outbreak.
: data from Tonghuashun, sub-sector classification according to the letter, data for reference.
. Meirui Medical is a typical beneficiary of the new crown outbreak.
Due to the impact of the new crown epidemic and bring ventilators, monitors and other life information and support anti-epidemic equipment demand increased, the company's anti-epidemic equipment has entered a large number of new high-end customer base at home and abroad, greatly shorten the company's brand and product promotion cycle, improve the company's overall product penetration in the high-end customer base.
addition, the company registered a large number of new coronavirus detection reagents and equipment and quickly put on the market, improving the performance of the enterprise.
, in the context of the New Crown outbreak, there are two main reasons why Hengrui Pharma has hardly been significantly affected: First, the harvest of innovative results.
the gradual harvest of innovation results has played a role in driving the company's performance growth, in recent years, the company's research and development investment has remained high, research and development investment intensity has exceeded many multinational pharmaceutical giants.
In the first half of this year, the company's research and development investment continued to climb, reaching 1,863 million yuan, an increase of 25.56 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 16.48 percent, strongly supporting the company's project research and development and innovation development.
is the optimization of the company's product structure.
with the restructuring of the company's products, the company's non-anti-tumor drug products represented by the imager maintained a stable growth trend.
company will continue to steadily promote the internationalization of research and development innovation and preparation products, while also focusing on the optimization of product structure to ensure sustainable growth of the company's performance.
: The data comes from the annual reports of listed companies.
, the drug Mingkangde is a leading CRO enterprise in China and the world, known as the "water seller" of innovative drugs.
Although the outbreak of the new crown has had a certain impact on the company's operations, but the company division to give full play to the "integrated, end-to-end" research and development service platform advantages, strengthen the upstream and downstream service sector between the customer transformation, from "following the development of the project" to "following the development of drug molecules", expanding services, continue to promote capacity and scale construction, the synergy between the various business sectors further enhanced.
, the size of revenue from each section of the business continues to grow.
: The data comes from the annual reports of listed companies.
in the face of the new form and new situation of marketing brought about by the outbreak of neo-crown pneumonia, the company actively adapts, acts quickly, and flexibly uses the close combination of online and offline methods, relying on a professional and detailed, covering a wide range of marketing teams, giving full play to the core advantages of "technology and market" two-wheel drive, promoting the company's product sales continued to grow, to ensure that the company's operating performance shows a good growth trend.
11 products are available or sold during the reporting period, covering infants, adults and the elderly, providing disease prevention and treatment solutions for all ages.
of these, four autonomous vaccine products are on sale, including AC-Hib, ACYW135 polysaccharid vaccine, Hib vaccine, AC brain polysaccharose-binding vaccine, and five proxy products are on sale, including Mercado's four-price HPV vaccine, nine-price HPV vaccine, five-price round vaccine and 23-price pneumonia vaccine, inactivated hepatitis A vaccine.
total operating income was RMB6,993,723,184.63, an increase of 38.80% over the same period last year, and net profit attributable to the owners of the parent company was RMB1,504,548,395.16, an increase of 31.18% over the same period last year.
: data from the same flower smooth, manual finishing, inevitably mistakes, data for reference.
.